Investigators found that dynamic BH3 profiling presented an excellent predictive capacity to anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors, that would facilitate their use in a clinical setting and complementing the readout of standard diagnostic assays.
[Cell Death & Disease]
